RadOnc Smart Review

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 10 builds a coherent curative strategy for resectable stage II through III non-small cell lung cancer. We show why a stage label alone cannot define medical operability, anatomic resectability, the required operation, the meaning of a PET-avid mediastinal node, or the best perioperative sequence.
The episode keeps radiation oncology engaged at the right moments: before a treatment path closes, when trimodality therapy is genuinely under consideration, and when response, margin status, residual nodal burden, or surgical findings reopen the local-risk calculation.

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 9 addresses one of the hardest surveillance problems after lung stereotactic body radiation therapy: distinguishing expected evolving fibrosis and inflammation from true local recurrence. We integrate time from treatment, serial morphology, metabolic behavior, symptoms, physiology, original dose geometry, restaging, and the feasibility of biopsy.
The second half turns suspicion into a salvage decision. The goal is to preserve a potentially curative opportunity without treating benign post-treatment change or causing disproportionate injury to previously irradiated thoracic organs.

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 8 explores the modifiers that can turn apparently early-stage non-small cell lung cancer into a high-risk radiation problem: central or ultracentral anatomy, endobronchial extension, large tumor size, and fibrotic interstitial lung disease. These features can change candidacy, fractionation, target priorities, image guidance, consent, and whether an ablative plan should be offered at all.
Rather than asking for a single central-lung dose, we ask which anatomic or patient-specific risk should control the recommendation and how to protect critical serial organs without pretending that every tradeoff can be solved by technique alone.

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 7 is a practical workshop in peripheral lung stereotactic body radiation therapy. We move from candidacy and respiratory-motion data to target construction, fractionation, chest-wall risk, intermediate-dose falloff, image guidance, and the question that matters at every fraction: can the team reproduce the geometry that made the plan acceptable?
The episode emphasizes why a small target and short course do not make this simple treatment. A geometric miss, hidden serial organ, unreliable motion envelope, or weak setup strategy carries a large biological consequence when each fraction delivers an ablative dose.

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 6 tackles early-stage non-small cell lung cancer as a treatment-selection problem, not a reflex comparison of surgery versus stereotactic body radiation therapy. We begin by confirming localized, node-negative disease, pursuing tissue when safely feasible, separating medical operability from anatomic resectability, and defining the actual operation and radiation course being compared.
Using a growing, FDG-avid peripheral lesion as the anchor, we make the diagnostic, functional, perioperative, and toxicity tradeoffs explicit so that the final recommendation remains conditional, multidisciplinary, and aligned with the patient’s informed goals.

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 5 moves thoracic radiation from the planning scan to the reality of treating a breathing patient. We examine how simulation, respiratory-motion assessment, treatment position, image registration, beam delivery, and image guidance must describe the same physical situation for the plan to remain trustworthy.
The episode provides a safety workflow for choosing a reproducible motion strategy, verifying the target or a justified surrogate, recognizing workflow failure, and escalating when treatment no longer behaves as designed. Throughout, we balance geometric confidence against treatment burden and complexity.

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 4 separates three questions that are too often collapsed into the phrase surgical candidate: Can the patient tolerate the proposed operation? Can the cancer be completely removed by a reasonable operation? And even if both are possible, is surgery the right oncologic strategy for this patient?
We apply those distinctions to pulmonary reserve, cardiac risk, frailty, extent of resection, nodal disease, margin feasibility, and patient preference. The result is a clearer way to defend curative surgery, a nonsurgical local option, or a multimodality sequence without hiding the real limiting factor.

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 3 connects thoracic nodal anatomy to the decisions it changes: imaging probability, procedural access, specimen adequacy, stage, and treatment intent. The goal is not simply to memorize station numbers, but to know whether a suspicious node was named correctly, could be reached by the chosen procedure, and was truly represented by an adequate sample.
We build a practical approach to invasive mediastinal staging that helps you explain what was sampled, what remains uncertain, and how the result should alter surgery, radiation, or multimodality treatment.

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 2 turns thoracic imaging and TNM staging into a clinical reasoning exercise rather than a table-lookup task. We work through how to integrate imperfect studies, separate radiographic suspicion from pathologic proof, and assign a transparent, version-correct anatomic stage without treating missing information as negative information.
The episode uses the American Joint Committee on Cancer Version 9 framework and emphasizes a repeatable sequence: confirm the diagnosis, assess whether imaging answers the staging questions, assign T, N, and M categories, translate the completed triplet, and clearly state any management-changing uncertainty.

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 1 follows the clinical chain from lung-cancer screening and pulmonary-nodule evaluation to a tissue diagnosis that can actually guide treatment. We focus on the decisions that prevent downstream staging and planning errors: whether an abnormality belongs on a screening or diagnostic pathway, what to sample, how to judge tissue adequacy, and when additional workup will change management.
Use the episode to practice a board-ready four-question framework: define the likely diagnosis, establish the known disease extent, identify the uncertainty most likely to change management, and state the realistic treatment intent.